A 6-month open-label extension study of the long-term safety of DVS SR [desvenlafaxine succinate sustained-release] in outpatients with fibromyalgia syndrome

Trial Profile

A 6-month open-label extension study of the long-term safety of DVS SR [desvenlafaxine succinate sustained-release] in outpatients with fibromyalgia syndrome

Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 15 Mar 2017

At a glance

  • Drugs Desvenlafaxine (Primary)
  • Indications Fibromyalgia
  • Focus Adverse reactions
  • Sponsors Wyeth
  • Most Recent Events

    • 15 Mar 2017 Status changed from completed to discontinued according to results published in the Clinical Pharmacology in Drug Development.
    • 05 Dec 2007 Status change from in progress to completed.
    • 14 Feb 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top